Bio Briefs
Posted By
Recent Posts on This Topic | See All >
-
Jan 03, 2012 Nature speaks with Keim about H5N1 studies -
-
-
Jun 20, 2011 Promising skin-cancer drug nears approval
Share on Twitter
Share on Facebook
Email to a friend
Print Article
TGen Clinical Research Services at Scottsdale Healthcare and Mayo Clinic study expands for new cancer drug
[Source: TGen] - TGen Clinical Research Services (TCRS) at Scottsdale Healthcare and Mayo Clinic are testing a new drug that may offer broad potential to treat solid tumors.
Clinical trials of the drug TH-302 are being conducted at TGen Clinical Research Services at Scottsdale Healthcare, a partnership of the Phoenix-based Translational Genomics Research Institute (TGen) and Scottsdale-based Scottsdale Healthcare Corp., and at Mayo Clinic in Arizona.
Dr. Glen Weiss, Director of Thoracic Oncology at TCRS at Scottsdale Healthcare, said the new drug appears promising and may be more effective and less toxic to healthy tissues than conventional drugs.
For more information click here.
Quick Links
- NEW: About the Arizona Center for Civic Leadership
- Arizona Biosciences News
- Arizona BioMap
- Roadmap Progress Updates
- Reports & Multimedia
- Timeline: Arizona's Bio Growth
- Arizona Bio Orgs on Twitter
- Arizona BioBasics
- The Biozona Brand
- Newsletter Signup
Download a new brochure from the Flinn Foundation outlining the 2011 progress on Arizona's Bioscienced Roadmap: a record high in bioscience jobs, plus gains in firms and venture-capital funding. Numerous achievements during the year advanced the core strategies of the Roadmap.
Also, read the full Performance Assessment describing in detail Arizona's 2011 progress on key Roadmap metrics.
